Sanofi

Sanofi S.A.

Type	Société Anonyme
Traded as	Euronext: SAN, NYSE: SNY, LSE: 0I42, FWB: SNW
Industry	Pharmaceuticals
Founded	20 August 2004 (by acquisition)
Headquarters	13th arrondissement, Paris, France
Key people	Chris Viehbacher (CEO), Serge Weinberg (Chairman)
Products	Prescription and over-the-counter drugs for thrombosis, cardiovascular disease, diabetes, central nervous system disorders, oncology and internal medicine, vaccines (list...)
Revenue	€30.38 billion (2010)[1]
Operating income	€5.961 billion (2010)[1]
Profit	€5.467 billion (2010)[1]
Total assets	€85.26 billion (end 2010)[1]
Total equity	€53.29 billion (end 2010)[1]
Employees	101,575 (end 2010)[1]
Subsidiaries	Genzyme, Sanofi Pasteur, Chattem, Zentiva
Website	www.sanofi.com

Sanofi S.A. is a multinational pharmaceutical company headquartered in Paris, France, the world's fourth-largest by prescription sales.^[2][3] Sanofi engages in the research and development, manufacturing and marketing of pharmaceutical products for sale principally in the prescription market, but the firm also develops over-the-counter medication. The company covers 7 major therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis and vaccines (it is the world's largest producer of the latter through its subsidiary Sanofi Pasteur).^[4] Sanofi is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA).^[5]

The company was formed as Sanofi-Aventis in 2004 by the merger of Aventis and Sanofi-Synthélabo. It changed its name to Sanofi in May 2011.

History

Sanofi-Synthélabo

Main article: Sanofi-Synthélabo

Sanofi-Synthélabo was formed in 1999 when Sanofi (former subsidiary of Total) merged with Synthélabo (former subsidiary of L'Oréal). The merged company was based in Paris, France.

Aventis

Main article: Aventis

Aventis was formed in 1999 when French company Rhône-Poulenc S.A. merged with the German corporation Hoechst Marion Roussel, which itself was formed from the 1995 merger of Hoechst AG with Roussel Uclaf and Marion Merrell Dow. The merged company was based in Schiltigheim, near Strasbourg, France.

Merger and beyond

Sanofi-Aventis was formed in 2004 when Sanofi-Synthélabo acquired Aventis. In early 2004, Sanofi-Synthélabo made a hostile takeover bid worth €47.8 billion for Aventis. Initially, Aventis rejected the bid because it felt that the bid offered inferior value based on the company's share value. The three-month takeover battle concluded when Sanofi-Synthélabo launched a friendly bid of €54.5 billion in place of the previously rejected hostile bid. French government intervention also played an active role. The French government, desiring what they called a "local solution", put heavy pressure on Sanofi-Synthélabo to raise its bid for Aventis after it became known that Novartis, a Swiss pharmaceutical company, was in the running.

October 2010: Sanofi-Aventis SA will lay off 1,700 US employees due to restructuring triggered by growing generic competition and other factors. The cuts being completed throughout 2011 according to transition needs. The layoffs amount to about 25 percents of the workers in the company's US pharmaceutical business. The company deny the action is related with acquisition plan of buying US biotech firm Genzyme Corp.^[6]

The company dropped the -Aventis suffix of its name on 6 May 2011 after receiving approval at its AGM. The reason given by the company for the change was to make its name easier to pronounce in countries such as China.^[7]

Business

Products

• Alfuzosin (Xatral) for benign prostatic hyperplasia
• Biprofined for pain
• Clopidogrel (Plavix, Iscover) for atherothrombosis
• Codeine (Solpadol) for Chronic pain
• Docetaxel (Taxotere) for breast, lung and prostate cancer
• Enoxaparin (Lovenox, Clexane) for thrombosis (its biggest seller in 2008)^[8]
• Fexofenadine (Allegra, Telfast) and Triamcinolone (Nasacort) for allergic rhinitis
• Glatiramer acetate (Copaxone) for multiple sclerosis
• Insulin glulisine (Apidra) and Insulin glargine (Lantus) for diabetes
• Irbesartan (Aprovel, Avapro, Delix, Karvea, Triatec, Tritace) for hypertension
• Menactra for meningitis
• Oxaliplatin (Eloxatin) for colorectal cancer
• Risedronic acid (Actonel) for osteoporosis and Paget’s disease
• Valproic acid (Depakine) and Valproate semisodium (Depakote) for epilepsy
• Zolpidem (Ambien, Ambien CR, Myslee, Stilnoct, Stilnox, Zolfresh, Zolt) for insomnia

The company also produces a broad range of over-the-counter products, among them IcyHot for muscle pain, Gold Bond for skin irritation, and Selsun Blue dandruff shampoo (these three brands were acquired in 2010 when Sanofi-Aventis purchased Chattem).

Management

• Serge Weinberg, Chairman
• Chris Viehbacher, CEO^[9]
• Jean-François Dehecq was the General Manager of Sanofi from its creation in 1973 until 2007.

Stockholders

As of 31 January 2011:^[1]

• Breakdown of share ownership: 5.16% by Total, 9.02% by L'Oréal, 0.46% treasury shares and 1.43% employees. The remaining 83.93% are publicly traded.
• Voting rights distribution: 8.89% to Total, 15.61% to L'Oréal, 2.33% to employees, and 73.17% to the public.

Head office

Head office in Paris

The head office is located in the 13th arrondissement of Paris, 174 Avenue de France. The architecture of the head office is of the predominate style of the area surrounding the François Mitterrand Library. After Sanofi and Aventis merged, the employees at the former Aventis head office in Schiltigheim, Alsace moved to Paris.^[10]

Collaborative research

In addition to internal research and development activities Sanofi is also involved in publicly funded collaborative research projects, with other industrial and academic partners. One example in the area of non-clinical safety assessment is the InnoMed PredTox.^[11][12] The company is expanding its activities in joint research projects within the framework of the Innovative Medicines Initiative of EFPIA and the European Commission.^[13]

In June 2010, Sanofi and the Charite University of Berlin signed a cooperation agreement for the research and development of medicines and therapies.^[14]

Aventis Foundation

The Aventis Foundation,^[15] a German charitable trust, was established in 1996 as the Hoechst Foundation with an endowment of €50 million. In 2000, the foundation was renamed the Aventis Foundation. Its aim is to promote music, theater, art, literature, higher education and healthcare research.

See also

	Paris portal
	Companies portal

• sanofi-aventis international BioGENEius Challenge
• Sanofi Pasteur

References

1. ^ ^{a b c d e f g} "Annual Report 2010". Sanofi-Aventis. http://en.sanofi-aventis.com/binaries/20F_2010_tcm28-30782.pdf. Retrieved 13 April 2011. 
2. ^ IMS Health 2008
3. ^ Keller, Greg (10 September 2008). "Sanofi names Viehbacher as new CEO". Associated Press (USA Today). http://www.usatoday.com/money/economy/2008-09-10-4035378426_x.htm. Retrieved 2009-04-19. 
4. ^ "Sanofi-Aventis to sign deal to build flu vaccine plant in China - source". AFX News (Forbes). 23 November 2007. http://www.forbes.com/feeds/afx/2007/11/23/afx4368351.html. Retrieved 2009-04-19. 
5. ^ "The Pharmaceutical Industry in Figures - 2008 Edition". European Federation of Pharmaceutical Industries and Associations (EFPIA). pp. 49. http://www.efpia.eu/content/default.asp?PageID=559&DocID=4883. Retrieved 2008-08-25. 
6. ^ Sanofi-Aventis To Lay Off 1,700 US Employees http://www.cbsnews.com/stories/2010/10/08/ap/health/main6939445.shtml
7. ^ Mennella, Noelle (6 May 2011). "Sanofi changes name, pace of acquisitions to slow". Reuters. http://www.reuters.com/article/2011/05/06/sanofi-idUSLDE74521Z20110506. Retrieved 7 May 2011. 
8. ^ "Annual Review 2008". Sanofi-Aventis. http://en.sanofi-aventis.com/binaries/Sanofi_RA_EN_tcm28-24842.pdf. Retrieved 2009-04-19. 
9. ^ Chris Viehbacher wird Nachfolger von Sanofi-Aventis-Chef Le Fur 10.09.2008
10. ^ "Sanofi-Aventis : regroupement à Paris." Le Journal du Net. Retrieved on 28 September 2010.
11. ^ Mattes WB (2008), Public consortium efforts in toxicogenomics, Methods Mol Biol. 2008;460:221-38 [1]
12. ^ "InnoMed PredTox Member Organizations". http://www.innomed-predtox.com/consortium/members/. Retrieved 2008-08-25. 
13. ^ Innovative Medicines Initiative. "IMI Call Topics 2008". IMI-GB-018v2-24042008-CallTopics.pdf. European Commission. http://imi.europa.eu/docs/calls01_en.zip. Retrieved 2008-08-25. ^{[dead link]}
14. ^ Sanofi-aventis, Charite University Sign Cooperation Agreement News article from InfoGrok.
15. ^ http://www.aventis-foundation.org/

External links

• Official website
• Aventis Foundation